Niagen Bioscience, Inc. Common Stock NAGE Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $6.32M+24.8% | $4.13M-42.4% | $4.58M+144% | $3.61M+24,160% | $5.06M+1,129% | ||
| $116K-26.6% | $139K-7.9% | $157K-4.3% | $158K-7.1% | $158K-11.2% | ||
| $1.72M+59.6% | $1.75M+132% | $1.76M+139% | $1.49M+25.6% | $1.08M+9.2% | ||
| $4.78M— | —— | —— | -$4K-300% | $0— | ||
| $85K+106% | —— | -$12K-200% | —— | -$1.32M-3,874% | ||
| $3.57M+79.3% | $2.04M+251% | $4.39M+553% | $3.22M+427% | $1.99M+198% | ||
| $2.48M+17.8% | —— | —— | $3.05M— | $2.11M+190% | ||
| -$101K-108% | $958K-13.5% | $1.32M+35.8% | -$1.67M+9.5% | $1.23M+26.9% | ||
| $169K+945% | -$746K-309% | -$87K-1,067% | -$268K-24.7% | -$20K+81.1% | ||
| -$12K+7.7% | -$18K0.0% | -$15K+28.6% | -$13K+35.0% | -$13K+38.1% | ||
| -$102K— | —— | —— | $95K+371% | $0-100% | ||
| $175K+373% | $60K+57.9% | $38K0.0% | $38K+2.7% | $37K-2.6% | ||
| -$241K+4.0% | -$236K+2.5% | -$233K-3.6% | -$229K-129% | -$251K-423% | ||
| $3.41M+268% | $1.26M— | -$1.16M— | $2.69M+120% | -$2.04M-245% | ||
| -$1.19M-115% | $679K-92.1% | $3.69M+5.6% | $1.25M— | $7.88M+2,572% | ||
| $5.8M— | —— | —— | —— | $0— | ||
| $5.25M+16,491% | -$101K-46.4% | -$24K-14.3% | -$135K-1,025% | -$32K+22.0% | ||
| $2.35M— | —— | —— | —— | $0— | ||
| $111K-96.4% | $228K-94.0% | $152K-85.4% | $3.75M+527% | $3.11M— | ||
| $0-100% | $2K0.0% | $4K0.0% | $3K+50.0% | $3K0.0% | ||
| $0-100% | $55K+34.1% | $0— | $6K— | $6K-45.5% | ||
| -$2.29M-174% | $0-100% | $148K-85.8% | $3.74M+528% | $3.11M+22,279% | ||
| $1.76M-83.9% | $498K-95.9% | $3.82M-15.4% | $4.86M+1,418% | $10.96M+4,465% | ||
| $175K+373% | $60K+57.9% | $38K0.0% | $38K+2.7% | $37K-2.6% | ||
| $116K-26.6% | $139K-7.9% | $157K-4.3% | $158K-7.1% | $158K-11.2% | ||
| $4.78M— | —— | —— | —— | $0— | ||
| —— | $495.75K— | $495.75K— | $495.75K— | $495.75K— | ||
| —— | $16.5K-20.5% | $16.5K-20.5% | $16.5K-20.5% | $16.5K-20.5% | ||
| $30K-54.5% | —— | —— | —— | $66K— | ||
| -$13K+96.8% | —— | -$16K-170% | —— | -$405K-1,257% | ||
| -$241K+4.0% | -$236K+2.5% | -$233K-3.6% | -$229K-129% | -$251K-423% | ||
| $3.41M+268% | $1.26M— | -$1.16M— | $2.69M+120% | -$2.04M-245% | ||
| $169K+945% | -$746K-309% | -$87K-1,067% | -$268K-24.7% | -$20K+81.1% | ||
| $114K— | —— | —— | —— | $0— | ||
| —— | $9.5K— | $9.5K— | $9.5K— | $9.5K— | ||
| $173K0.0% | —— | $164K0.0% | $159K-2.5% | $173K-0.6% | ||
| —— | $166.25K-0.7% | $166.25K-0.7% | $166.25K-0.7% | $166.25K-0.7% | ||
| -$12K+7.7% | -$18K0.0% | -$15K+28.6% | -$13K+35.0% | -$13K+38.1% | ||
| $85K+106% | —— | -$12K-200% | —— | -$1.32M-3,874% | ||
| —— | $0+100% | $0+100% | $0+100% | $0+100% | ||
| $494K— | —— | —— | —— | $0— | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| —— | $73K+79.1% | $73K+79.1% | $73K+79.1% | $73K+79.1% | ||
| $61K+90.6% | —— | $24K-41.5% | $135K+1,025% | $32K-22.0% | ||
| $0-100% | $2K0.0% | $4K0.0% | $3K+50.0% | $3K0.0% | ||
| $0-100% | $55K+34.1% | $0— | $6K— | $6K-45.5% | ||
| $47K— | —— | —— | —— | $0— | ||
| —— | $1.37M— | $1.37M— | $1.37M— | $1.37M— | ||
| -$102K— | —— | —— | $95K— | $0— | ||
| -$241K+4.0% | -$236K+2.5% | -$233K-3.6% | -$229K-129% | -$251K-423% | ||
| $226K-23.4% | $236K-2.5% | $233K+72.6% | $109K-17.4% | $295K+224% | ||
| —— | $281.75K— | $281.75K— | $281.75K— | $281.75K— | ||
| $0-100% | —— | —— | —— | $1.13M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Niagen Bioscience, Inc. Common Stock generate?
- Niagen Bioscience, Inc. Common Stock (NAGE) generated $4.4M in operating cash flow over the trailing twelve months.
- Where does Niagen Bioscience, Inc. Common Stock's cash flow data come from?
- Every line is extracted from Niagen Bioscience, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
